公开(公告)号：US20250067741A1

公开(公告)日：2025-02-27

申请号：US18720675

申请日：2022-12-16

Applicant: UNIVERSITÄT ZÜRICH

Inventor： Irina BANZOLA ,  Blaz PAVLOVIC ,  Nagjie Laila ALIJAJ ,  Daniel EBERLI

IPC: G01N33/574

Abstract: The present invention relates to the field of assessment of the health status, particular with regard to prostate cancer risk, by measurement of certain proteins in human samples, in particular in human urine.

公开(公告)号：US20250060367A1

公开(公告)日：2025-02-20

申请号：US18452504

申请日：2023-08-18

Applicant: EARLI Inc.

Inventor： David SUHY ,  Paul ESCARPE ,  Cyriac ROEDING ,  Justin LIN ,  Alex HARWIG ,  Shireen RUDINA ,  Leland Harrison HARTWELL

IPC: G01N33/574

Abstract: The present disclosure encompasses embodiments of nucleic acids comprising genetic elements which are useful for the detection of diseased cells.

公开(公告)号：US12228575B2

公开(公告)日：2025-02-18

申请号：US17214966

申请日：2021-03-29

Applicant: KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES

Inventor： Jin Su Kim ,  Hyeongi Kim ,  Javeria Zaheer

IPC: C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to a biomarker composition for predicting the prognosis of cancer malignancy induced by exposure to microplastics and use thereof, and more particularly, it was confirmed that the expression level of CD44, E-cadherin, N-cadherin, PD-L1, NPAS2, NR1D1, DNMT1, SLC7A2, PCDH7 and CLDN7 was changed in cancer cell lines and animal models treated with polystyrene microspheres which are the one type of microplastic for 4 weeks, and malignancy was induced due to an increase in proliferation, migration and invasion of cancer cells by the change in the expression level of the gene, and 5-year overall survival rates in gastric cancer patients decreased and thus the genes may be provided as a biomarker composition for predicting the prognosis of cancer malignancies by exposure to microplastics.

公开(公告)号：US12227727B2

公开(公告)日：2025-02-18

申请号：US16992705

申请日：2019-02-27

Applicant: Pop Test Oncology LLC

Inventor： Randice Lisa Altschul ,  Neil David Theise ,  Razvan Andrei Ene ,  Myron Rapkin ,  Rebecca O'Brien

IPC: A61M5/142 ,  A61B5/00 ,  A61B5/145 ,  A61M1/16 ,  A61M1/34 ,  A61M1/36 ,  C12M1/00 ,  C12M1/12 ,  C12M3/00 ,  C12M3/06 ,  G01N33/574 ,  A61B5/021 ,  A61B34/20

Abstract: The present invention provides for a method and apparatus for inserting and using dermal interstitial sensors in, for example, an analyte monitoring system, and for injecting active pharmaceutical ingredients, a bio-artificial organ device, and detection of a protein biomarker.

公开(公告)号：US12227592B2

公开(公告)日：2025-02-18

申请号：US17310296

申请日：2020-01-29

Applicant: THE ASAN FOUNDATION ,  EDISBIOTECH CO., LTD. ,  UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION

Inventor： Seung-Jae Myung ,  Eun-Ju Do ,  Jayoung Kang ,  Hye-Nam Son ,  Hyori Kim ,  A-Neum Lee ,  Yeong Hui Cho

IPC: C07K16/00 ,  C07K16/32 ,  G01N33/574

Abstract: The present invention relates to a monoclonal antibody which specifically binds to an EGF2 domain of colon cancer secreted protein-2 (CCSP-2), or an antigen-binding fragment thereof. The monoclonal antibody or the antigen-binding fragment thereof of the present invention specifically binds to the EGF2 domain of CCSP-2, and thus has significantly increased affinity compared with existing peptides specifically binding to CCSP-2 and further increased specificity compared with existing antibodies to CCSP-2. Therefore, in future, accurate diagnosis can be achieved by specific detection of CCSP-2 in the protein level.

公开(公告)号：US12226467B2

公开(公告)日：2025-02-18

申请号：US17738570

申请日：2022-05-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K38/00 ,  A61K35/17 ,  A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C07K14/72 ,  C07K14/725 ,  C07K14/81 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C12N5/0783 ,  C12N9/02 ,  C12N9/12 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G16B25/00 ,  G16B25/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20250054144A1

公开(公告)日：2025-02-13

申请号：US18920871

申请日：2024-10-19

Applicant: Ventana Medical Systems, Inc.

Inventor： Michael Barnes ,  Joerg Bredno ,  Rebecca C. Bowermaster ,  Srinivas Chukka ,  Wen-Wei Liu ,  Kandavel Shanmugam ,  Junming Zhu

IPC: G06T7/00 ,  G01N33/574 ,  G16H10/00

Abstract: Immune context scores are calculated for tumor tissue samples using continuous scoring functions. Feature metrics for at least one immune cell marker are calculated for a region or regions of interest, the feature metrics including at least a quantitative measure of human CD3 or total lymphocyte counts. A continuous scoring function is then applied to a feature vector including the feature metric and at least one additional metric related to an immunological biomarker, the output of which is an immune context score. The immune context score may then be plotted as a function of a diagnostic or treatment metric, such as a prognostic metric (e.g. overall survival, disease-specific survival, progression-free survival) or a predictive metric (e.g. likelihood of response to a particular treatment course). The immune context score may then be incorporated into diagnostic and/or treatment decisions.

公开(公告)号：US20250052758A1

公开(公告)日：2025-02-13

申请号：US18806426

申请日：2024-08-15

Applicant: PIERRE FABRE MEDICAMENT

Inventor： Pierre FERRÉ ,  Francisco CRUZALEGUI ,  Noureddine LOUKILI ,  Olivier DELFOUR ,  Edward Thein Htun VAN DER HORST

IPC: G01N33/574 ,  A61P35/00 ,  C07K16/28

Abstract: The present disclosure provides methods for modulating (e.g., preventing, inhibiting, blocking) the interaction of PSGL-1 and VISTA with agents (e.g., antibodies) that bind to PSGL-1 and/or VISTA.

公开(公告)号：US20250051472A1

公开(公告)日：2025-02-13

申请号：US18719086

申请日：2022-12-19

Applicant: Dana-Farber Cancer Institute, Inc.

Inventor： Barbel Schrofelbauer ,  Patrick Kimes ,  William Hahn

IPC: C07K16/28 ,  A61K45/06 ,  A61K47/68 ,  G01N33/574

Abstract: Aspects of the invention are drawn to a recombinant monoclonal antibodies and methods of using the same.

公开(公告)号：US12224067B1

公开(公告)日：2025-02-11

申请号：US18934152

申请日：2024-10-31

Applicant: Progenics Pharmaceuticals, Inc.

Inventor： Mark R. Baker

IPC: G06K9/00 ,  G01N33/574 ,  G06Q10/00 ,  G16H15/00 ,  G16H30/20 ,  G16H30/40 ,  G16H50/20 ,  G16H50/30 ,  G16H50/70

Abstract: Described herein is a platform and supported graphical user interface (GUI) decision-making tools for use by medical practitioners and/or their patients, e.g., to aide in the process of making decisions about a course of cancer treatment and/or to track treatment and/or the progress of a disease.